Summary & Overview
HCPCS G9138: Non-Hodgkin's Lymphoma Diagnostic Evaluation
HCPCS Level II code G9138 designates an oncology diagnostic evaluation for disease status in non-Hodgkin's lymphoma when staging is not determined, including assessments for possible relapse or non-response to therapy. The code is specific to Medicare-approved demonstration projects and captures comprehensive clinical reassessment when standard staging designations are unavailable. Nationally, this code matters for oncology care coordination, reporting within demonstration initiatives, and accurate capture of complex diagnostic encounters that inform treatment planning.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context, the typical sites of service where it is used, and the implications for billing and documentation in demonstration settings. The publication outlines benchmarks where available, notes policy and program context relevant to Medicare demonstration projects, and summarizes clinical scenarios that commonly trigger use of the code. Data not provided in the input for specific associated taxonomies, ICD-10 diagnoses, or related codes is noted as unavailable.
This summary provides a national perspective for payers, billing professionals, and oncology clinicians seeking to understand the purpose and application of G9138 in diagnostic evaluations for non-Hodgkin's lymphoma.
Billing Code Overview
HCPCS Level II code G9138 describes a diagnostic evaluation related to non-Hodgkin's lymphoma when disease status or staging is not determined. The code is intended for use in Medicare-approved demonstration projects and covers evaluations for possible relapse, non-response to therapy, or cases not otherwise listed in standard staging assessments.
Service type: Oncology diagnostic evaluation
Typical site of service: Oncology clinic, hospital outpatient department, or other outpatient diagnostic setting
Data not available in the input for payers, associated taxonomies, ICD-10 diagnoses, related codes, and detailed service line.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a prior diagnosis of non-Hodgkin's lymphoma presents to a cancer center with new systemic symptoms (fever, night sweats, weight loss) and enlarging lymphadenopathy following recent chemotherapy. The treating oncologist orders a diagnostic evaluation to determine disease status, assess for relapse versus refractory disease, and to guide further therapy. The workflow includes outpatient oncology clinic assessment, review of prior pathology and staging, targeted imaging (PET/CT), laboratory studies including LDH and complete blood count, and coordination of tissue sampling (excisional lymph node biopsy or core needle biopsy) when imaging suggests progressive disease. The diagnostic evaluation may occur in an outpatient oncology clinic, hospital outpatient department, ambulatory surgical center, or inpatient setting if the patient is acutely ill. Documentation includes history of present illness, prior treatment regimens, response to therapy, rationale for testing, signed informed consent for biopsy or procedures, and detailed interpretation of imaging and pathology to support billing for G9138 under a Medicare-approved demonstration project.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when services require substantially greater work than typical (e.g., extensive diagnostic evaluation beyond standard for staging). |